CLARITY PHARMA RESEARCH ®
PHARMACEUTICAL MARKET RESEARCH REPORTS BASED IN SCIENCE ™

Pulmonology / infectious disease

Nontuberculous mycobacteria pulmonary disease – A variety of strains cause this rare infectious lung disease. We conducted 7-nation market sizing studies and have compared treatment patterns for NTMPD in the US, Europe, and Asia.

We captured detailed information about current treatment practices, patient characteristics and disease states, and other medications used as therapy, with the goal of helping the client to see where its product might fill gaps. We also have studied refractory populations and the burden of illness in several nations.

Findings on some of this research have been published in medical journals and at international medical conferences, as shown in the "Related Articles or Presentations" column on this page.

We also have studied other lung-related conditions, including chronic obstructive pulmonary disease (COPD), asthma, sarcoidosis and forms of lung cancer.

Related Articles or Presentations

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference, 2 poster presentations on findings from an economic burden of illness study of a rare infection in Europe and Canada Poster1; Poster2
European Respiratory Journal, co-author, research letter on poor adherence to treatment guidelines for a rare pulmonary disease Abstract
ISPOR conference, retrospective observational study to capture economic burden evidence in a rare disease Abstract; Poster
EphMRA, “Precedent and consequence research to undergird orphan reimbursement strategy – A multi-layered, non-traditional approach” Presentation
Japanese Respiratory Society, treatment patterns for a rare lung disease in EU5, Japan and US Abstract
European Respiratory Society, prevalence and incidence of a rare lung disease in Europe Abstract
European Respiratory Society, treatment patterns for rare disease in EU5, Japan and US Abstract
European Respiratory Journal, treatment patterns for a rare lung infection in Europe, US and Japan, and article on prevalence in Europe, co-written with international team of medical experts, Abstract 1& 2
KIT 2014 (Congress for Infectious Diseases and Tropical Medicine), co-author, rare lung infection prevalence in Germany Abstract
Annals of the American Thoracic Society, US study of rare lung infection Abstract
American Thoracic Society (ATS) International Conference, study of rare lung infection Abstract

CLARITY PHARMA RESEARCH ®​PHARMACEUTICAL MARKET RESEARCH REPORTS BASED IN SCIENCE ™

CLARITY PHARMA RESEARCH ®
PHARMACEUTICAL MARKET RESEARCH REPORTS BASED IN SCIENCE ™